MarketResearchReports.com: The Market Value for Monoclonal Antibodies …SBWire (press release)Lewes, DE — (SBWIRE) — 12/31/2013 — The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase f…
RTT NewsMortality Rates High For Women With RA AntibodiesRTT NewsPostmenopausal women with rheumatoid arthritis anti-bodies may be at a higher risk for mortality than those without, according to a new study from researchers at the University of Pittsbu…
FDA Turns Down MS Drug LemtradaMedPage TodayHe indicated that biologic agents targeting specific immune cell classes — the anti-CD25 drug daclizumab (Zenepax) and the B-cell depleting agent ocrelizumab — also were promising for MS. Alemtuzumab had pr…
|
2013 – A Year We Will Never Forget
ProHealth … Myalgic Encephalomyelitis,” featured a roster of noted physicians and researchers: Dan Peterson and Andreas Kogelnik, who shared the keynote address; Mady Hornig on pathogen discovery in ME; Olav Mella and Oystein Fluge speaking about Rituximab, … |
BioLineRX Ltd. : BioLineRx Highlights Initial Phase 2 Results of Acute Myeloid …4-traders (press release)Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow m…
Using the Immune System to Fight LupusdailyRxRituximab (brand name Rituxan) targets B cells to decrease their number. It has been approved for use in leukemias, lymphomas and autoimmune diseases involving B cells. However, a clinical trial using rituxi…
ProHealth |
The 2nd International Symposium For CFS/ME Overview By Rosamund Vallings …
ProHealth Other interventions include rituximab, cytokine blockers and GcMAF. [Dr. Peterson’s assertion that a drug can be a ‘biomarker’ refers to the idea of segregating patients according to their response to treatment, and then digging into their physiology … |
MedPage Today10 Questions: Robert Spiera, MDMedPage TodayIn the ensuing nearly 2 decades, many other such biologics have been developed for the treatment of rheumatoid arthritis, lupus, and with the demonstration of the efficacy of rituximab in ANCA-as…
MedscapeTop 10 Highlights From The Liver MeetingMedscapeInterim analysis of hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy: a prospective study. Program and abstracts of the 64th Annual Meeting…
|
Biologic Makers Thwart Generics: Winning Stocks
YCharts Hospira (HSP) and Teva halted late-stage development of follow-on versions of Roche AG’s monoclonal antibody Rituxan (rituximab) — $3.1 billion in domestic sales, trailing 12-months – due to rising R&D costs. Similar to strategies used to delay entry … |